Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
JAMA Dermatology2013Vol. 149(5), pp. 637–637
Citations Over TimeTop 18% of 2013 papers
Sara Samimi, Emily Chu, John Seykora, Alison W. Loren, Carmela C. Vittorio, Alain H. Rook, Misha Rosenbach, Ellen J. Kim
Abstract
Dasatinib, a thiazole carboxamide derivative, is a second-generation tyrosine kinase inhibitor (TKI), similar in structure to imatinib, that is used for the treatment of chronic myelogenous leukemia (CML). We report a case of extensive dasatinib-induced leukotrichia in a patient with refractory CML.
Related Papers
- → Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia(2013)12 cited
- → Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia(2009)9 cited
- → Dasatinib: ten years of clinical practice worldwide(2016)2 cited
- → Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia(2010)1 cited